Toshio Fujino, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proto-Oncogene Proteins c-met | 4 | 2022 | 579 | 1.410 |
Why?
|
| Lung Neoplasms | 20 | 2023 | 13112 | 1.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 9 | 2023 | 5230 | 0.720 |
Why?
|
| Protein Kinase Inhibitors | 12 | 2023 | 5532 | 0.700 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2019 | 98 | 0.660 |
Why?
|
| Drug Resistance, Neoplasm | 11 | 2023 | 5170 | 0.650 |
Why?
|
| Exons | 6 | 2023 | 2438 | 0.570 |
Why?
|
| Leukemia | 1 | 2019 | 1509 | 0.380 |
Why?
|
| Mutation | 16 | 2023 | 29777 | 0.380 |
Why?
|
| Carcinoma | 1 | 2021 | 2375 | 0.350 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2019 | 2942 | 0.340 |
Why?
|
| Hodgkin Disease | 1 | 2014 | 1415 | 0.280 |
Why?
|
| Pneumonectomy | 3 | 2020 | 1098 | 0.240 |
Why?
|
| Quinazolines | 2 | 2021 | 1356 | 0.230 |
Why?
|
| Genes, erbB-1 | 1 | 2023 | 161 | 0.220 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2014 | 2248 | 0.200 |
Why?
|
| Aniline Compounds | 3 | 2023 | 986 | 0.190 |
Why?
|
| Acrylamides | 2 | 2021 | 255 | 0.190 |
Why?
|
| Pyridazines | 1 | 2022 | 202 | 0.190 |
Why?
|
| Triazines | 1 | 2022 | 315 | 0.180 |
Why?
|
| Ethylnitrosourea | 1 | 2019 | 51 | 0.180 |
Why?
|
| Quinazolinones | 2 | 2018 | 221 | 0.170 |
Why?
|
| Anilides | 1 | 2022 | 409 | 0.170 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 2727 | 0.170 |
Why?
|
| Alkylating Agents | 1 | 2019 | 139 | 0.170 |
Why?
|
| Interleukin-3 | 1 | 2019 | 444 | 0.160 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 426 | 0.160 |
Why?
|
| Thrombophilia | 1 | 2020 | 305 | 0.150 |
Why?
|
| Thymoma | 1 | 2019 | 186 | 0.150 |
Why?
|
| Quinolines | 1 | 2022 | 732 | 0.150 |
Why?
|
| Blood Coagulation Disorders | 1 | 2020 | 337 | 0.150 |
Why?
|
| Fibrinogen | 1 | 2020 | 894 | 0.140 |
Why?
|
| Benzamides | 1 | 2022 | 1383 | 0.140 |
Why?
|
| Lymphangitis | 1 | 2016 | 12 | 0.140 |
Why?
|
| Thymus Neoplasms | 1 | 2019 | 268 | 0.140 |
Why?
|
| Imidazoles | 1 | 2022 | 1206 | 0.130 |
Why?
|
| Gene Amplification | 1 | 2020 | 1063 | 0.130 |
Why?
|
| Piperidines | 1 | 2022 | 1601 | 0.120 |
Why?
|
| Pyrimidines | 2 | 2022 | 2945 | 0.110 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 1937 | 0.110 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 1070 | 0.110 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 1240 | 0.100 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2019 | 808 | 0.090 |
Why?
|
| Renal Dialysis | 1 | 2019 | 1783 | 0.090 |
Why?
|
| Receptor, erbB-2 | 1 | 2018 | 2418 | 0.080 |
Why?
|
| Preoperative Period | 2 | 2021 | 550 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 11036 | 0.080 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 1670 | 0.080 |
Why?
|
| Humans | 22 | 2023 | 743811 | 0.080 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 2529 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2019 | 19232 | 0.060 |
Why?
|
| Positron-Emission Tomography | 2 | 2017 | 6237 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 4033 | 0.050 |
Why?
|
| Animals | 7 | 2023 | 168660 | 0.050 |
Why?
|
| Aged | 9 | 2021 | 163178 | 0.050 |
Why?
|
| Postoperative Complications | 2 | 2021 | 15281 | 0.050 |
Why?
|
| Mice | 6 | 2023 | 81154 | 0.040 |
Why?
|
| Mediastinal Cyst | 1 | 2019 | 29 | 0.040 |
Why?
|
| Drug Tolerance | 1 | 2021 | 376 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 12954 | 0.040 |
Why?
|
| Fibrinolysis | 1 | 2020 | 322 | 0.040 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 16674 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 6363 | 0.040 |
Why?
|
| Mutagenesis, Insertional | 1 | 2021 | 654 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 733 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 11524 | 0.030 |
Why?
|
| Survival Rate | 2 | 2020 | 12786 | 0.030 |
Why?
|
| Prognosis | 3 | 2021 | 29052 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2021 | 1531 | 0.030 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 57744 | 0.030 |
Why?
|
| Cell Line | 2 | 2018 | 15993 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 1691 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2019 | 1356 | 0.030 |
Why?
|
| Male | 7 | 2021 | 349776 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2021 | 1660 | 0.030 |
Why?
|
| Carboplatin | 1 | 2016 | 801 | 0.030 |
Why?
|
| Female | 9 | 2021 | 380020 | 0.030 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 1256 | 0.030 |
Why?
|
| Piperazines | 1 | 2021 | 2487 | 0.020 |
Why?
|
| Transfection | 1 | 2018 | 5892 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 6895 | 0.020 |
Why?
|
| Pyridines | 1 | 2021 | 2827 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2016 | 1705 | 0.020 |
Why?
|
| Cell Survival | 1 | 2018 | 5881 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2021 | 2375 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2021 | 5986 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 35409 | 0.020 |
Why?
|
| Sex Factors | 1 | 2021 | 10394 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 3047 | 0.020 |
Why?
|
| Time Factors | 2 | 2019 | 40038 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 20121 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2017 | 9848 | 0.020 |
Why?
|
| Middle Aged | 4 | 2021 | 213241 | 0.020 |
Why?
|
| Prevalence | 1 | 2021 | 15211 | 0.010 |
Why?
|
| Age Factors | 1 | 2021 | 18355 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 11360 | 0.010 |
Why?
|
| Phenotype | 1 | 2021 | 16361 | 0.010 |
Why?
|
| Lung | 1 | 2021 | 9858 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2021 | 63042 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2018 | 10477 | 0.010 |
Why?
|
| Disease Progression | 1 | 2019 | 13273 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 15526 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 39001 | 0.010 |
Why?
|
| Risk Factors | 1 | 2021 | 72252 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2020 | 77410 | 0.010 |
Why?
|
| Adult | 1 | 2017 | 213889 | 0.000 |
Why?
|